Shock Syndromes II
Madsen TE, Simmons J, Choo EK, Portelli D, McGregor
AJ, Napoli AM. The DISPARITY study: do gender dif-
ferences exist in Surviving Sepsis Campaign resuscitation
bundle completion, completion of individual bundle ele-
e7-11. https://doi.org/10.1016/j.jcrc.2014.01.002
McKinley BA, Kozar RA, Cocanour CS, et al.
Normal
versus
supranormal
oxygen
delivery
goals in shock resuscitation: the response is the
same. J Trauma. 2002;53(5):825-832. https://doi.
org/10.1097/00005373-200211000-00004
Meizoso JP, Dudaryk R, Mulder MB, et al. Increased risk
of fibrinolysis shutdown among severely injured trauma
patients receiving tranexamic acid. J Trauma Acute
Care Surg. 2018;84(3):426-432. https://doi.org/10.1097/
ta.0000000000001792
Milling TJ Jr, Refaai MA, Sarode R, et al. Safety of a
four-factor prothrombin complex concentrate versus
plasma for vitamin k antagonist reversal: an integrated
analysis of two phase IIIb clinical trials. Acad Emerg
Med.
2016;23(4):466-475.
https://doi.org/10.1111/
acem.12911
Moore HB, Moore EE, Chapman MP, et al. Plasma-
first resuscitation to treat haemorrhagic shock during
emergency ground transportation in an urban area: a
https://doi.org/10.1016/s0140-6736(18)31553-8
Morrison JJ, Ross JD, Dubose JJ, Jansen JO, Midwinter
MJ, Rasmussen TE. Association of cryoprecipitate
and tranexamic acid with improved survival following
wartime injury: findings from the MATTERs II study.
jamasurg.2013.764
Murphy GJ, Pike K, Rogers CA, et al. Liberal or
restrictive transfusion after cardiac surgery. N Engl J
Med. 2015;372(11):997-1008. https://doi.org/10.1056/
nejmoa1403612
Myles PS, Smith JA, Forbes A, et al. Tranexamic acid
in patients undergoing coronary-artery surgery. N Engl
J Med. 2017;376(2):136-148. https://doi.org/10.1056/
nejmoa1606424
Neal MD, Hoffman MK, Cuschieri J, et al. Crystalloid
to packed red blood cell transfusion ratio in the mas-
sively transfused patient: when a little goes a long way.
J Trauma Acute Care Surg. 2012;72(4):892-898. https://
doi.org/10.1097/ta.0b013e31823d84a7
Nutescu EA, Dager WE, Kalus JS, et al. Management of
bleeding and reversal strategies fo r o r a l a n t i c o a g-
u l a n t s: cl i n i c a l p r a c t i c e c o n s i d e r a t i o n s .
org/10.2146/ajhp130243
O’Shea RS, Davitkov P, Ko CW, et al. AGA clinical prac-
tice guideline on the management of coagulation disorders in
patients with cirrhosis. Gastroenterology. 2021;161(5):1615-
1627.e1. https://doi.org/10.1053/j.gastro.2021.08.015
Panteli M, Pountos I, Giannoudis PV. Pharmacological
adjuncts to stop bleeding: options and effectiveness. Eur
J Trauma Emerg Surg. 2016;42(3):303-310. https://doi.
org/10.1007/s00068-015-0613-x
Peltan ID, Vande Vusse LK, Maier RV, Watkins TR.
An international normalized ratio-based definition of
acute traumatic coagulopathy is associated with mor-
tality, venous thromboembolism, and multiple organ
1438. https://doi.org/10.1097/ccm.0000000000000981
Pham TN, Cancio LC, Gibran NS; American Burn
Association. American Burn Association practice
guidelines burn shock resuscitation. J Burn Care
Res.
2008;29(1):257-266.
https://doi.org/10.1097/
bcr.0b013e31815f3876
Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab
for dabigatran reversal—full cohort analysis. N Engl
J Med. 2017;377(5):431-441. https://doi.org/10.1056/
nejmoa1707278
Porter JM, Ivatury RR. In search of the optimal
end points of resuscitation in trauma patients: a
review. J Trauma. 1998;44(5):908-914. https://doi.
org/10.1097/00005373-199805000-00028
Prochaska M, Salcedo J, Berry G, Meltzer D. Racial
differences in red blood cell transfusion in hospitalized
patients with anemia. Transfusion. 2022;62(8):1519-
1526. https://doi.org/10.1111/trf.16935
Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and
safety of a 4-factor prothrombin complex concentrate in
patients on vitamin K antagonists presenting with major
bleeding: a randomized, plasma-controlled, phase IIIb
study. Circulation. 2013;128(11):1234-1243. https://doi.
org/10.1161/circulationaha.113.002283
Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet
alfa for the reversal of factor Xa inhibitor activity. N Engl
J Med. 2015;373(25):2413-2424. https://doi.org/10.1056/
nejmoa1510991